Biotech Values

[oc631]

And the random occasional liver failure seems a little bit of a concern.

Obviously the drug won't make it past the FDA if this is an issue.

Altogether I wouldn't expect the Abbott regimen to be a blockbuster in the sense of draining the reserve of patients that have so far put off treatment.

The only way I see ABT's combo becoming a blockbuster is at GILD's misfortune. There's a lot of potential upside for ABT that's not priced into the stock IMO.